GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » EPS without NRI

GRI Bio (GRI Bio) EPS without NRI : $-30.59 (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is GRI Bio EPS without NRI?

GRI Bio's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-1.47. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-30.59.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for GRI Bio's EPS without NRI or its related term are showing as below:

GRI's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.1
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

GRI Bio's EPS (Diluted) for the three months ended in Dec. 2023 was $-1.44. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-30.28.

GRI Bio's EPS (Basic) for the three months ended in Dec. 2023 was $-1.44. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-30.28.


GRI Bio EPS without NRI Historical Data

The historical data trend for GRI Bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRI Bio EPS without NRI Chart

GRI Bio Annual Data
Trend Dec21 Dec22 Dec23
EPS without NRI
-3.81 -6.85 -28.64

GRI Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only -5.37 -5.52 -19.88 -3.72 -1.47

Competitive Comparison of GRI Bio's EPS without NRI

For the Biotechnology subindustry, GRI Bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GRI Bio's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GRI Bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where GRI Bio's PE Ratio without NRI falls into.



GRI Bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GRI Bio  (NAS:GRI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


GRI Bio EPS without NRI Related Terms

Thank you for viewing the detailed overview of GRI Bio's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


GRI Bio (GRI Bio) Business Description

Traded in Other Exchanges
N/A
Address
2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Executives
David Leslie Szekeres director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson director 20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro officer: Chief Medical Officer 828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz director, 10 percent owner, officer: Chief Executive Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi officer: Chief Scientific Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne director 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly officer: Chief Financial Officer C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell director 1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc. 10 percent owner 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren officer: SVP, Regul Affairs & Prog Mgmt C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi director C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer director, 10 percent owner C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon 10 percent owner SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052

GRI Bio (GRI Bio) Headlines

From GuruFocus

GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio

By Marketwired 06-27-2023